GSK is one of the world’s leading science-based global healthcare companies. We employ thousands of people around the world and, together, we’re addressing some of the biggest questions our industry and the world around us have to offer: Is there a cure for cancer? What does healthy mean? How can we help people to do more, feel better and live longer? Join us and you’ll play your part in helping us find the answers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMA TECH

AEQUUS ANNOUNCES HEALTH CANADA NOTICE OF COMPLIANCE (NOC) FOR ZIMED® PRESERVATIVE FREE (BIMATOPROST 0.03%)

Aequus Pharmaceuticals | December 21, 2022

news image

Aequus Pharmaceuticals Inc. is pleased to announce that Health Canada has approved Zimed® PF for the reduction of elevated intraocular pressure in patients with open-angled glaucoma or ocular hypertension. Affecting more than 700,000 people in Canada, glaucoma is one of the leading causes of blindness in North America. Zimed® PF is the first prostaglandin analog that is preservative free and offered in an easy-to-use multi-dose bottle in Canada. PGAs are commonly prescribe...

Read More

OCUPHIRE PHARMA ANNOUNCES IN-LICENSE OF PHASE 2 ORAL SMALL MOLECULE DRUG CANDIDATE FOR DIABETIC RETINOPATHY

Business Wire | January 22, 2020

news image

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first-in-class, orally-adminis...

Read More

Business Insights

NOVARTIS ANNOUNCES NEW ORGANIZATIONAL STRUCTURE TO ACCELERATE GROWTH STRENGTHEN PIPELINE AND INCREASE PRODUCTIVITY

Novartis Pharma AG | April 04, 2022

news image

Novartis announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade. “The simpler organizational model we are unveiling today is central to our growth strategy as it will make us more agile and competitive, enhance patient and customer orientation, unlock significant potential in our R&D pip...

Read More

Business Insights

ANKURA LAUNCHES PHARMACEUTICAL DATA INTEGRITY SOLUTION

Ankura | March 09, 2022

news image

Ankura Consulting, LLC a leading global expert services and advisory firm announced the expansion of its Pharmaceutical and Biopharma Regulatory Compliance offering with the addition of a Pharmaceutical Data Integrity solution within the Data and Technology practice, bolstering its comprehensive client advisory capabilities. With this solution, Ankura has enhanced its team of experts to support pharmaceutical clients' compliance with the Data Integrity guidelines of multiple r...

Read More
news image

Business Insights, PHARMA TECH

AEQUUS ANNOUNCES HEALTH CANADA NOTICE OF COMPLIANCE (NOC) FOR ZIMED® PRESERVATIVE FREE (BIMATOPROST 0.03%)

Aequus Pharmaceuticals | December 21, 2022

Aequus Pharmaceuticals Inc. is pleased to announce that Health Canada has approved Zimed® PF for the reduction of elevated intraocular pressure in patients with open-angled glaucoma or ocular hypertension. Affecting more than 700,000 people in Canada, glaucoma is one of the leading causes of blindness in North America. Zimed® PF is the first prostaglandin analog that is preservative free and offered in an easy-to-use multi-dose bottle in Canada. PGAs are commonly prescribe...

Read More
news image

OCUPHIRE PHARMA ANNOUNCES IN-LICENSE OF PHASE 2 ORAL SMALL MOLECULE DRUG CANDIDATE FOR DIABETIC RETINOPATHY

Business Wire | January 22, 2020

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first-in-class, orally-adminis...

Read More
news image

Business Insights

NOVARTIS ANNOUNCES NEW ORGANIZATIONAL STRUCTURE TO ACCELERATE GROWTH STRENGTHEN PIPELINE AND INCREASE PRODUCTIVITY

Novartis Pharma AG | April 04, 2022

Novartis announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade. “The simpler organizational model we are unveiling today is central to our growth strategy as it will make us more agile and competitive, enhance patient and customer orientation, unlock significant potential in our R&D pip...

Read More
news image

Business Insights

ANKURA LAUNCHES PHARMACEUTICAL DATA INTEGRITY SOLUTION

Ankura | March 09, 2022

Ankura Consulting, LLC a leading global expert services and advisory firm announced the expansion of its Pharmaceutical and Biopharma Regulatory Compliance offering with the addition of a Pharmaceutical Data Integrity solution within the Data and Technology practice, bolstering its comprehensive client advisory capabilities. With this solution, Ankura has enhanced its team of experts to support pharmaceutical clients' compliance with the Data Integrity guidelines of multiple r...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us